Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia
- PMID: 16963676
- DOI: 10.1378/chest.130.3.787
Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia
Abstract
Background: While current guidelines recommend consideration of local microbiologic data when selecting empiric treatment for hospital-acquired pneumonia (HAP), few specifics of how to do this have been offered.
Methods: We conducted a retrospective analysis of HAP pathogens in 111 consecutive patients who acquired HAP during July to December 2004 and had a corresponding positive culture finding for a bacterial pathogen. These data were used to develop institution-specific guidelines.
Results: The most common bacteria identified were Staphylococcus aureus, Acinetobacter baumannii, and Pseudomonas aeruginosa, which were associated with 38%, 25%, and 19% of pneumonias, respectively. Susceptibility of Gram-negative bacteria to piperacillin-tazobactam and cefepime was 80% and 81%, respectively. The isolation of organisms resistant to piperacillin-tazobactam or cefepime was significantly more frequent in patients who had been hospitalized > or = 10 days. Of Gram-negative isolates resistant to piperacillin-tazobactam or cefepime, ciprofloxacin was active against < 10%, while amikacin was active against > 80%. New treatment guidelines were developed that divided the American Thoracic Society/Infectious Diseases Society of America "late onset/risk of multidrug-resistant pathogens" group of patients into two subcategories: "early-late" pneumonias (< 10 days of hospitalization) and "late-late" pneumonias (> or = 10 days of hospitalization). Guideline-directed treatment regimens would be predicted to provide adequate initial therapy for > 90% of late-onset pneumonias at our institution.
Conclusions: Current guidelines suggest adding either an aminoglycoside or a fluoroquinolone to beta-lactam therapy for empiric Gram-negative coverage. However, in our institution, adding ciprofloxacin would not appreciably enhance the likelihood of providing initial appropriate antibiotic coverage. This underscores the importance of employing a systematic analysis of local data when developing treatment guidelines.
Similar articles
-
Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit.Surg Infect (Larchmt). 2012 Dec;13(6):352-9. doi: 10.1089/sur.2011.056. Surg Infect (Larchmt). 2012. PMID: 23268613
-
Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.Clin Ther. 2009 Nov;31(11):2765-78. doi: 10.1016/j.clinthera.2009.11.026. Clin Ther. 2009. PMID: 20110018
-
[Guidelines for treatment of pneumonia in intensive care units].Infez Med. 2005;Suppl:7-17. Infez Med. 2005. PMID: 16801748 Review. Italian.
-
Current guidelines for the treatment of severe pneumonia and sepsis.Chemotherapy. 2005 Aug;51(5):227-33. doi: 10.1159/000087452. Chemotherapy. 2005. PMID: 16103664 Review.
-
Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms.Infection. 2005 Jun;33(3):129-35. doi: 10.1007/s15010-005-4021-8. Infection. 2005. PMID: 15940413
Cited by
-
Collaborative Antimicrobial Stewardship: Working with Microbiology.Infect Dis Clin North Am. 2020 Mar;34(1):51-65. doi: 10.1016/j.idc.2019.10.006. Epub 2019 Dec 10. Infect Dis Clin North Am. 2020. PMID: 31836331 Free PMC article. Review.
-
Ventilator-Associated Pneumonia Due to MRSA vs. MSSA: What Should Guide Empiric Therapy?Antibiotics (Basel). 2022 Jun 24;11(7):851. doi: 10.3390/antibiotics11070851. Antibiotics (Basel). 2022. PMID: 35884105 Free PMC article.
-
Initial empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children: a retrospective medical record review.BMC Infect Dis. 2022 Nov 21;22(1):866. doi: 10.1186/s12879-022-07881-7. BMC Infect Dis. 2022. PMID: 36404302 Free PMC article.
-
Update of the treatment of nosocomial pneumonia in the ICU.Crit Care. 2020 Jun 29;24(1):383. doi: 10.1186/s13054-020-03091-2. Crit Care. 2020. PMID: 32600375 Free PMC article. Review.
-
An Argument for the Use of Aminoglycosides in the Empiric Treatment of Ventilator-Associated Pneumonia.Surg Infect (Larchmt). 2016 Jun;17(3):329-33. doi: 10.1089/sur.2015.276. Epub 2016 Apr 1. Surg Infect (Larchmt). 2016. PMID: 27035615 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical